Wednesday October 13, 2004 (4:16 pm ET) UBS Upgrades Lincare to Buy The therapy provider's stock rose after the government recommended a higher dispensing fee for respiratory therapies UBS Financial upgraded Lincare (LNCR) to buy from neutral. Analyst Justin Lake says according to a just-released, finalized General Accounting Office report, the Centers for Medicare and Medicaid Services has recommended a monthly dispensing fee for respiratory medications of between $55 and $64, which is at the very high end of expectations. He notes his previous estimate had included a conservative estimate regarding size of a dispensing fee in the $20-per-month range. Lake raised Lincare's $1.55 2005 earnings per share estimate to $1.90, and upped the $33 target to $38, (based on shares trading at 20 times the 2005 earnings per share estimate). He also raised Apria Healthcare's $1.85 2005 earnings per share estimate to $1.95.